Somewhat Positive News Coverage Somewhat Unlikely to Affect Aratana Therapeutics (PETX) Stock Price

Press coverage about Aratana Therapeutics (NASDAQ:PETX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.7568183776025 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

PETX has been the subject of a number of research reports. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the company a “buy” rating in a research report on Tuesday, January 16th. CL King initiated coverage on Aratana Therapeutics in a research report on Wednesday, December 27th. They set a “neutral” rating for the company. Zacks Investment Research cut Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Stifel Nicolaus reissued a “hold” rating and set a $6.00 price objective on shares of Aratana Therapeutics in a research report on Monday, December 18th. Finally, Jefferies Group reissued a “buy” rating and set a $8.00 price objective on shares of Aratana Therapeutics in a research report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Aratana Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.55.

Aratana Therapeutics (NASDAQ PETX) traded down $0.14 during midday trading on Friday, reaching $4.18. The company’s stock had a trading volume of 215,714 shares, compared to its average volume of 494,504. Aratana Therapeutics has a one year low of $3.91 and a one year high of $7.67. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $173.91, a price-to-earnings ratio of -2.88 and a beta of 3.06.

In other Aratana Therapeutics news, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $6.53, for a total transaction of $760,849.48. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Peter Steven St sold 19,367 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total value of $92,380.59. Following the transaction, the chief executive officer now owns 672,259 shares in the company, valued at $3,206,675.43. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,056,399 shares of company stock worth $6,087,271. Corporate insiders own 5.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply